Sandoz receives Health Canada approval for PrJubbonti®, first and only denosumab biosimilar for treatment of osteoporosis.
May 31, 2024
Health Canada has provided authorization to market PrJubbonti® (denosumab subcutaneous injection, reference medicine: Prolia).
PrJubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass. This human monoclonal antibody and RANK ligand inhibitor (bone metabolism regulator) is approved to treat all five indications covered by the reference medicine and is available as a 60 mg/mL solution in single-use prefilled syringe. PrJubbonti® should be available on the Canadian market in the coming months.
“This announcement means that Canadians will have greater access to an important biologic therapy in the treatment of osteoporosis,” says Dr. Famida Jiwa, President and CEO, Osteoporosis Canada. “Health Canada’s approval of the denosumab biosimilar PrJubbonti®will expand and increase access to patients who are living with osteoporosis.”
Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]
Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
July 7, 2026
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
